2019 logo_150x35_jpg.jpg
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
April 30, 2020 16:05 ET | Novan, Inc.
Enrollment of first patient targeted for September 2020Top line results expected late in the second quarter of 2021 based on anticipated timeline MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE)...
2019 logo_150x35_jpg.jpg
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
April 20, 2020 16:05 ET | Novan, Inc.
Engages H.C. Wainwright & Co. as strategic and financial advisorNITRICIL™ nitric oxide technology platform has enabled multiple early and late-stage pipeline opportunities in dermatology, women’s...
2019 logo_150x35_jpg.jpg
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
April 03, 2020 08:15 ET | Novan, Inc.
Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
2019 logo_150x35_jpg.jpg
Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
March 26, 2020 16:05 ET | Novan, Inc.
MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct...
2019 logo_150x35_jpg.jpg
Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market
March 24, 2020 08:10 ET | Novan, Inc.
MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional...
2019 logo_150x35_jpg.jpg
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
March 23, 2020 08:15 ET | Novan, Inc.
Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including...
2019 logo_150x35_jpg.jpg
Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter’s Option to Purchase Additional Securities
March 03, 2020 16:05 ET | Novan, Inc.
MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten public...
2019 logo_150x35_jpg.jpg
Novan Announces Pricing of $5.5 Million Public Offering
February 27, 2020 23:20 ET | Novan, Inc.
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public...
2019 logo_150x35_jpg.jpg
Novan Announces Proposed Public Offering
February 27, 2020 16:01 ET | Novan, Inc.
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common...
2019 logo_150x35_jpg.jpg
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
February 20, 2020 08:15 ET | Novan, Inc.
Provides funds to evaluate the mechanistic antiviral activity of WH602Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant...